COVID-19 Impact on Global Oncology Small Molecule Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Oncology Small Molecule Drugs Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Oncology Small Molecule Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Chemotherapy Drugs
  • 1.4.3 Immunomodulating Drugs
  • 1.4.4 Targeted Therapy Drugs
  • 1.4.5 Hormonal Therapy
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Oncology Small Molecule Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Blood Cancer
  • 1.5.3 Breast Cancer
  • 1.5.4 Gastrointestinal Cancer
  • 1.5.5 Prostate Cancer
  • 1.5.6 Lung Cancer
  • 1.5.7 Other
• 1.6 Coronavirus Disease 2019 (Covid-19): Oncology Small Molecule Drugs Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Oncology Small Molecule Drugs Industry
    • 1.6.1.1 Oncology Small Molecule Drugs Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Oncology Small Molecule Drugs Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Oncology Small Molecule Drugs Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Oncology Small Molecule Drugs Market Perspective (2015-2026)
• 2.2 Oncology Small Molecule Drugs Growth Trends by Regions
  • 2.2.1 Oncology Small Molecule Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Oncology Small Molecule Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Oncology Small Molecule Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Oncology Small Molecule Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Oncology Small Molecule Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Oncology Small Molecule Drugs Players by Market Size
  • 3.1.1 Global Top Oncology Small Molecule Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Oncology Small Molecule Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Oncology Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Oncology Small Molecule Drugs Market Concentration Ratio
  • 3.2.1 Global Oncology Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Oncology Small Molecule Drugs Revenue in 2019
• 3.3 Oncology Small Molecule Drugs Key Players Head office and Area Served
• 3.4 Key Players Oncology Small Molecule Drugs Product Solution and Service
• 3.5 Date of Enter into Oncology Small Molecule Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Oncology Small Molecule Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Type (2021-2026)

5 Oncology Small Molecule Drugs Breakdown Data by Application (2015-2026)

• 5.1 Global Oncology Small Molecule Drugs Market Size by Application (2015-2020)
• 5.2 Global Oncology Small Molecule Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Oncology Small Molecule Drugs Market Size (2015-2020)
• 6.2 Oncology Small Molecule Drugs Key Players in North America (2019-2020)
• 6.3 North America Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 6.4 North America Oncology Small Molecule Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Oncology Small Molecule Drugs Market Size (2015-2020)
• 7.2 Oncology Small Molecule Drugs Key Players in Europe (2019-2020)
• 7.3 Europe Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 7.4 Europe Oncology Small Molecule Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China Oncology Small Molecule Drugs Market Size (2015-2020)
• 8.2 Oncology Small Molecule Drugs Key Players in China (2019-2020)
• 8.3 China Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 8.4 China Oncology Small Molecule Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Oncology Small Molecule Drugs Market Size (2015-2020)
• 9.2 Oncology Small Molecule Drugs Key Players in Japan (2019-2020)
• 9.3 Japan Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 9.4 Japan Oncology Small Molecule Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Oncology Small Molecule Drugs Market Size (2015-2020)
• 10.2 Oncology Small Molecule Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia Oncology Small Molecule Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India Oncology Small Molecule Drugs Market Size (2015-2020)
• 11.2 Oncology Small Molecule Drugs Key Players in India (2019-2020)
• 11.3 India Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 11.4 India Oncology Small Molecule Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Oncology Small Molecule Drugs Market Size (2015-2020)
• 12.2 Oncology Small Molecule Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Oncology Small Molecule Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America Oncology Small Molecule Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview and Its Total Revenue
  • 13.1.3 Roche Oncology Small Molecule Drugs Introduction
  • 13.1.4 Roche Revenue in Oncology Small Molecule Drugs Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 Novartis
  • 13.2.1 Novartis Company Details
  • 13.2.2 Novartis Business Overview and Its Total Revenue
  • 13.2.3 Novartis Oncology Small Molecule Drugs Introduction
  • 13.2.4 Novartis Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.2.5 Novartis Recent Development
• 13.3 Pfizer
  • 13.3.1 Pfizer Company Details
  • 13.3.2 Pfizer Business Overview and Its Total Revenue
  • 13.3.3 Pfizer Oncology Small Molecule Drugs Introduction
  • 13.3.4 Pfizer Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.3.5 Pfizer Recent Development
• 13.4 Celgene
  • 13.4.1 Celgene Company Details
  • 13.4.2 Celgene Business Overview and Its Total Revenue
  • 13.4.3 Celgene Oncology Small Molecule Drugs Introduction
  • 13.4.4 Celgene Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.4.5 Celgene Recent Development
• 13.5 Bristol-Myers Squibb
  • 13.5.1 Bristol-Myers Squibb Company Details
  • 13.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  • 13.5.3 Bristol-Myers Squibb Oncology Small Molecule Drugs Introduction
  • 13.5.4 Bristol-Myers Squibb Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.5.5 Bristol-Myers Squibb Recent Development
• 13.6 Amgen
  • 13.6.1 Amgen Company Details
  • 13.6.2 Amgen Business Overview and Its Total Revenue
  • 13.6.3 Amgen Oncology Small Molecule Drugs Introduction
  • 13.6.4 Amgen Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.6.5 Amgen Recent Development
• 13.7 Johnson & Johnson
  • 13.7.1 Johnson & Johnson Company Details
  • 13.7.2 Johnson & Johnson Business Overview and Its Total Revenue
  • 13.7.3 Johnson & Johnson Oncology Small Molecule Drugs Introduction
  • 13.7.4 Johnson & Johnson Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.7.5 Johnson & Johnson Recent Development
• 13.8 AbbVie
  • 13.8.1 AbbVie Company Details
  • 13.8.2 AbbVie Business Overview and Its Total Revenue
  • 13.8.3 AbbVie Oncology Small Molecule Drugs Introduction
  • 13.8.4 AbbVie Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.8.5 AbbVie Recent Development
• 13.9 Sanofi
  • 13.9.1 Sanofi Company Details
  • 13.9.2 Sanofi Business Overview and Its Total Revenue
  • 13.9.3 Sanofi Oncology Small Molecule Drugs Introduction
  • 13.9.4 Sanofi Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.9.5 Sanofi Recent Development
• 13.10 Takeda
  • 13.10.1 Takeda Company Details
  • 13.10.2 Takeda Business Overview and Its Total Revenue
  • 13.10.3 Takeda Oncology Small Molecule Drugs Introduction
  • 13.10.4 Takeda Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 13.10.5 Takeda Recent Development
• 13.11 Eli Lilly
  • 10.11.1 Eli Lilly Company Details
  • 10.11.2 Eli Lilly Business Overview and Its Total Revenue
  • 10.11.3 Eli Lilly Oncology Small Molecule Drugs Introduction
  • 10.11.4 Eli Lilly Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.11.5 Eli Lilly Recent Development
• 13.12 Bayer
  • 10.12.1 Bayer Company Details
  • 10.12.2 Bayer Business Overview and Its Total Revenue
  • 10.12.3 Bayer Oncology Small Molecule Drugs Introduction
  • 10.12.4 Bayer Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.12.5 Bayer Recent Development
• 13.13 AstraZeneca
  • 10.13.1 AstraZeneca Company Details
  • 10.13.2 AstraZeneca Business Overview and Its Total Revenue
  • 10.13.3 AstraZeneca Oncology Small Molecule Drugs Introduction
  • 10.13.4 AstraZeneca Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.13.5 AstraZeneca Recent Development
• 13.14 Astellas
  • 10.14.1 Astellas Company Details
  • 10.14.2 Astellas Business Overview and Its Total Revenue
  • 10.14.3 Astellas Oncology Small Molecule Drugs Introduction
  • 10.14.4 Astellas Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.14.5 Astellas Recent Development
• 13.15 Merck
  • 10.15.1 Merck Company Details
  • 10.15.2 Merck Business Overview and Its Total Revenue
  • 10.15.3 Merck Oncology Small Molecule Drugs Introduction
  • 10.15.4 Merck Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.15.5 Merck Recent Development
• 13.16 Biogen Idec
  • 10.16.1 Biogen Idec Company Details
  • 10.16.2 Biogen Idec Business Overview and Its Total Revenue
  • 10.16.3 Biogen Idec Oncology Small Molecule Drugs Introduction
  • 10.16.4 Biogen Idec Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.16.5 Biogen Idec Recent Development
• 13.17 Eisai
  • 10.17.1 Eisai Company Details
  • 10.17.2 Eisai Business Overview and Its Total Revenue
  • 10.17.3 Eisai Oncology Small Molecule Drugs Introduction
  • 10.17.4 Eisai Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.17.5 Eisai Recent Development
• 13.18 Teva
  • 10.18.1 Teva Company Details
  • 10.18.2 Teva Business Overview and Its Total Revenue
  • 10.18.3 Teva Oncology Small Molecule Drugs Introduction
  • 10.18.4 Teva Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.18.5 Teva Recent Development
• 13.19 Otsuka
  • 10.19.1 Otsuka Company Details
  • 10.19.2 Otsuka Business Overview and Its Total Revenue
  • 10.19.3 Otsuka Oncology Small Molecule Drugs Introduction
  • 10.19.4 Otsuka Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.19.5 Otsuka Recent Development
• 13.20 Ipsen
  • 10.20.1 Ipsen Company Details
  • 10.20.2 Ipsen Business Overview and Its Total Revenue
  • 10.20.3 Ipsen Oncology Small Molecule Drugs Introduction
  • 10.20.4 Ipsen Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.20.5 Ipsen Recent Development
• 13.21 Gilead Sciences
  • 10.21.1 Gilead Sciences Company Details
  • 10.21.2 Gilead Sciences Business Overview and Its Total Revenue
  • 10.21.3 Gilead Sciences Oncology Small Molecule Drugs Introduction
  • 10.21.4 Gilead Sciences Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.21.5 Gilead Sciences Recent Development
• 13.22 Exelixis
  • 10.22.1 Exelixis Company Details
  • 10.22.2 Exelixis Business Overview and Its Total Revenue
  • 10.22.3 Exelixis Oncology Small Molecule Drugs Introduction
  • 10.22.4 Exelixis Revenue in Oncology Small Molecule Drugs Business (2015-2020)
  • 10.22.5 Exelixis Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer